7-trifluoromethyl-9H-β-carboline | 1232100-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7-trifluoromethyl-9H-β-carboline
• 英文别名: 7-trifluoromethyl-β-carboline；9H-Pyrido[3,4-b]indole, 7-(trifluoromethyl)-；7-(trifluoromethyl)-9H-pyrido[3,4-b]indole
• CAS: 1232100-30-9
• 化学式: C₁₂H₇F₃N₂
• 分子量: 236.196
• InChiKey: UEQGBTJIWXDXDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-(2-bromo-5-(trifluoromethyl)phenyl)pyridin-3-amine 在 palladium diacetate 、 potassium carbonate 、 tricyclohexylphosphine tetrafluoroborate 、 三甲基乙酸 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 4.0h， 以58.6 mg的产率得到7-trifluoromethyl-9H-β-carboline
  参考文献：
  名称：

  Structure–Activity Relationships of Carboline and Carbazole Derivatives as a Novel Class of ATP-Competitive Kinesin Spindle Protein Inhibitors

  摘要：

  The kinesin spindle protein (KSP) is a mitotic kinesin involved in the establishment of a functional bipolar mitotic spindle during cell division. It is considered to be an attractive target for cancer chemotherapy with reduced side effects. Based on natural product scaffold-derived fused indole-based inhibitors and known biphenyl-type KSP inhibitors, various carboline and carbazole derivatives were synthesized and biologically evaluated. beta-Carboline and lactam-fused carbazole derivatives exhibited remarkably potent KSP inhibitory activity and mitotic arrest in prometaphase with formation of an irregular monopolar spindle. The planar tri- and tetracyclic analogs inhibited KSP ATPase in an ATP-competitive manner just like biphenyl-type inhibitors.

  DOI：

  10.1021/jm200448n

文献信息

• Substituted beta-carbolines
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1209158A1

  公开（公告）日：2002-05-29

  Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IκB kinase is involved.

  式I的化合物适用于生产用于预防和治疗在其过程中涉及IκB激酶活性增加的疾病的药物。
• Substituted beta carbolines
  申请人：——

  公开号：US20020099068A1

  公开（公告）日：2002-07-25

  The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, 1 which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I&kgr;B kinase is involved.

  本发明的主题是新型取代的β-咔啉类化合物，具体为公式I的化合物，适用于用于预防和治疗在其过程中I&kgr;B激酶活性增加的疾病的药物的生产。
• [EN] SUBSTITUTED BETA-CARBOLINES WITH IKB-KINASE INHIBITING ACTIVITY<br/>[FR] BETA-CARBOLINES SUBSTITUEES AYANT UNE ACTIVITE INHIBITRICE DE L'IKB-KINASE
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2001068648A1

  公开（公告）日：2001-09-20

  Compounds of the formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IλB kinase is involved.

  式(I)的化合物适用于生产用于预防和治疗在其过程中涉及IλB激酶活性增加的疾病的药物。
• Substituted beta-carbolines as lkB kinase inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1134221A1

  公开（公告）日：2001-09-19

  Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NFκB is involved.

  式 I 的化合物 适用于生产预防和治疗因 NFκB 活性增强而引起的疾病的药物。
• SUBSTITUTED BETA-CARBOLINES WITH IKB-KINASE INHIBITING ACTIVITY
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1268477B1

  公开（公告）日：2010-04-21